Drug Profile
Research programme: SMO protein antagonists - Amgen
Alternative Names: smoothened protein antagonist - AmgenLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Amgen
- Class Phthalazines; Small molecules
- Mechanism of Action SMO protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
- 16 Nov 2010 Preclinical pharmacodynamics data presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2010)
- 17 Aug 2009 Preclinical trials in Cancer in USA (unspecified route)